Woodland Biofuels Closes Equity Investment to Help Build Ethanol Demonstration Plant

Woodland Biofuels announced today the closing of a common equity investment in Woodland to help build a groundbreaking demonstration plant that will efficiently produce cellulosic ethanol from renewable wastes.

The common equity investment is part of a $12 million demonstration plant financing. Investors include the Ontario Emerging Technologies Fund (OETF), Investeco Capital, and David LeGresley, former Vice-Chairman of National Bank Financial. OETF is a $250 million fund established by the Province of Ontario to co-invest alongside qualified investors in innovative, high-growth, private Ontario companies. Investeco Capital is a private equity firm focussed primarily on high-growth companies with lasting competitive advantages.

The demonstration plant will use Woodland's patented technology, which can produce sustainable fuels from virtually any type of biomass, including wood waste, agricultural waste and municipal waste. The technology generates no toxic emissions and eliminates the need to use food, such as corn, to produce ethanol.

"We are excited to be part of this important step towards the commercialization of Woodland's process," said Andrew Heintzman, President of Investeco Capital. "The potential of the opportunity is truly enormous, and we believe the Woodland team has the skills and ability to execute."

"We expect this demonstration plant to show that Woodland will be the lowest cost producer of automotive fuel in North America," said Greg Nuttall, President and CEO of Woodland. "This financing further validates Woodland's technology and business, moving us another step closer to leadership in the biofuels market."

The plant will be located at the Bioindustrial Innovation Centre, in the University of Western Ontario's Sarnia-Lambton Research Park.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.